research The PDE4 inhibitor, apremilast, suppresses experimentally induced alopecia areata in human skin in vivo
Apremilast may help treat hair loss in alopecia areata.
Search
for
Did you mean PDE4 inhibitors?
Sort by
Research
30 / 133 resultsresearch Drug repurposing of cyclin-dependent kinase inhibitors for neutrophilic acute respiratory distress syndrome and psoriasis
In this study, researchers report that CDK inhibitors like palbociclib and ribociclib, initially developed for cancer therapy, show potential in treating neutrophilic inflammation-related conditions such as ARDS and psoriasis, although their clinical repurposing requires further research on safety and dose adjustments.
research The relative efficacy of monotherapy with Janus kinase inhibitors, dupilumab and apremilast in adults with alopecia areata: Network meta‐analyses of clinical trials
In this study, JAK inhibitors like baricitinib and ruxolitinib were found to be more effective and caused fewer discontinuations due to adverse events in adults with alopecia areata compared to therapies like dupilumab and apremilast, highlighting the need for more high-quality comparative trials.
research Phosphodiesterase (PDE) Inhibitors for the Treatment of Inflammatory Skin Conditions
PDE inhibitors, especially PDE4 inhibitors like apremilast, are effective for certain inflammatory skin conditions but have side effects and can be costly.
research Systematic review of newer agents for the management of alopecia areata in adults: Janus kinase inhibitors, biologics and phosphodiesterase‐4 inhibitors
This review suggests that oral Janus kinase inhibitors are a promising treatment for alopecia areata in adults, showing significant hair regrowth with fewer side effects than conventional treatments, while PDE-4 inhibitors and biologics show limited efficacy.
research Alopecia areata
This article reviews current and emerging treatments for alopecia areata, including Janus kinase inhibitors, highlighting variability in clinical outcomes and the lack of sustained remission.
research Alopecia areata: Animal models illuminate autoimmune pathogenesis and novel immunotherapeutic strategies
This review explores animal models of alopecia areata, particularly focusing on the insights they've provided into the disease's immune mechanisms and potential treatment approaches, without reporting new experimental data.
research The Changing Landscape of Alopecia Areata: The Therapeutic Paradigm
This review discusses recent advances and ongoing clinical trials in novel therapeutics for alopecia areata, despite the lack of current FDA-approved treatments for severe cases, and reports no new results.
research A novel therapeutic paradigm for patients with extensive alopecia areata
This review discusses immune pathways involved in alopecia areata and explores emerging, more targeted therapeutic strategies, noting their potential for better safety and effectiveness compared to traditional immune suppressants.
research Lack of efficacy of apremilast in 9 patients with severe alopecia areata
This article hypothesizes that apremilast, a phosphodiesterase 4 inhibitor, could be a targeted treatment for alopecia areata due to its ability to suppress interferon-gamma production, but reports no new clinical results.
research Apremilast and tofacitinib exert differential effects in the humanized mouse model of alopecia areata
No results are provided in this article as it lacks an available abstract, making it unclear what effects apremilast and tofacitinib have in a humanized mouse model of alopecia areata.
research Seborrheic Dermatitis Revisited: Pathophysiology, Diagnosis, and Emerging Therapies—A Narrative Review
This review of seborrheic dermatitis highlights the role of complex immunoinflammatory processes in its pathogenesis and discusses emerging treatments, such as PDE4 inhibitors, JAK inhibitors, and microbiome-targeted therapies, which may benefit patients with severe or treatment-resistant forms, according to the authors.
research From mechanisms to therapies: current advances breakthroughs in alopecia areata immunopathology
This review discusses the complex role of immune disturbances and the JAK-STAT pathway in alopecia areata, noting the success of JAK inhibitors in treatment, while highlighting ongoing debates and challenges in targeting other pathways like IL-17 and TNF-α.
research Alopecia Areata: A Complex Cytokine Driven Disease
This research discusses the complex immune pathogenesis of alopecia areata and highlights the success of Jak inhibitors and IL-4Rα antagonists, while IL-17A and PDE4 inhibitors showed limited efficacy; controlled trials are advocated to better understand cytokine involvement.
research Dupilumab for alopecia areata treatment: A double‐edged sword?
This case report highlights the onset of alopecia areata following dupilumab treatment, noting the significant temporal link between the medication use and hair loss occurrence.
research Crisaborole as a Potential Treatment for Pediatric Alopecia Areata: A Case Report and Literature Review
This case report suggests that crisaborole may be an effective alternative treatment for alopecia areata in pediatric patients, showing significant hair regrowth after two weeks in a 10-year-old girl.
research 1113 Targeting anti-inflammatory immunonanocarriers to human and murine neutrophils via Ly6 antigen for psoriasiform dermatitis alleviation
This study found that NIMP-R14-conjugated nanoparticles, loaded with roflumilast, effectively targeted neutrophils to reduce inflammation and improve symptoms in a mouse model of psoriasiform dermatitis, suggesting potential for targeted therapy in autoimmune skin diseases.
research Pyroptosis in Alopecia Areata: Synthesizing Emerging Hypotheses and Charting a Path to New Therapies
In this review, researchers reported that pyroptosis, a type of inflammatory cell death linked to inflammasome activity, is a key factor in the pathogenesis of alopecia areata and may present new therapeutic opportunities, though most treatments are still in early research stages.
research Alopesi Tedavisinde Kullanılan İlaç Tedavileri ve Yeni Yaklaşımlar
This study reviews current pharmacological treatments for alopecia, highlighting minoxidil, 5α-reductase inhibitors, JAK inhibitors, and other agents, and notes ongoing research aimed at improving their effectiveness and safety profiles.
research A retrospective review of paediatric alopecia areata cases seen in a tertiary institution in Singapore
Most children with alopecia areata improved with treatment, but those with more hair loss had worse outcomes.
research Apremilast treatment of atopic dermatitis and other chronic eczematous dermatoses
This study observed that apremilast treatment improved skin lesions and reduced pruritus in patients with chronic, severe atopic dermatitis and one case of hand and foot dermatitis.
research Monovalent antibody-conjugated lipid-polymer nanohybrids for active targeting to desmoglein 3 of keratinocytes to attenuate psoriasiform inflammation
This study found that actively targeted AN2728-loaded nanocarriers reduced inflammation and improved skin condition in a mouse model of psoriasiform inflammation compared to free drug and non-targeted nanoparticles.
research Exploring the Complexities of Atopic Dermatitis: Pathophysiological Mechanisms and Therapeutic Approaches
This review discusses the connections between atopic dermatitis and alopecia areata, emphasizing shared mechanisms and potential overlapping treatments, but it does not report new clinical findings.
research Phosphodiesterase inhibitors and prostaglandin analogues in dermatology: A comprehensive review
This review found that oral and topical phosphodiesterase inhibitors and topical prostaglandin analogues are safe and effective treatments for various skin diseases, including psoriasis, atopic dermatitis, vitiligo, and alopecia.
research The use of phosphodiesterase inhibitors for the treatment of alopecia
This review discusses the use of phosphodiesterase inhibitors for alopecia, finding promising preliminary results with topical caffeine for androgenetic alopecia and telogen effluvium, but limited success in alopecia areata.
research 277 An open label pilot clinical trial of the JAK inhibitor tofacitinib for alopecia areata
In this open-label trial, tofacitinib showed dramatic clinical responses in most patients with moderate-to-severe alopecia areata, supporting further research into JAK inhibitors for this condition.
research Biologic Therapies and Small-Molecule Inhibitors for Dissecting Cellulitis of the Scalp: A Systematic Review
This study reviews the efficacy and safety of advanced therapies like TNFα inhibitors and IL-17/IL-23 inhibitors for dissecting cellulitis of the scalp, finding TNFα inhibitors particularly effective for severe or refractory cases, although prospective validation is needed for early intervention benefits.
research Comment on ‘Androgenetic alopecia is associated with increased scalp hardness’: role of phosphodiesterase inhibitors?
This letter to the editor comments on the association between androgenetic alopecia and increased scalp hardness, exploring the possible role of phosphodiesterase inhibitors but provides no new clinical results.
research A randomized placebo-controlled single-center pilot study of the safety and efficacy of apremilast in subjects with moderate-to-severe alopecia areata
Apremilast was not effective in treating moderate-to-severe alopecia areata.
research Editorial: Exploring innovative therapies for rare inflammatory skin diseases
This study reviews advances in targeted therapies for moderate-severe dermatological conditions like plaque psoriasis and atopic dermatitis, reporting on newly approved treatments and highlighting the need for further innovations in managing rare inflammatory skin diseases through emerging laboratory techniques and trials.